Daniel A. Ermann, MD, on First-Line Therapy for CLL: Real-World Outcomes Among Medicare Beneficiaries
ASCO 2026
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
The ASCO Post Staff
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.
The ASCO Post Staff
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).
For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).
The ASCO Post Staff
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).
The ASCO Post Staff
Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patients with advanced or metastatic urothelial carcinoma (Abstract 4517).
